SuppreMol launched as a new company
SuppreMol is working on the development of drugs for the treatment of autoimmune diseases and allergies through innovative therapeutic approaches centred on Fc -receptors. The development of these drugs is based on patent rights owned by the Max-Planck-Society and licensed to SuppreMol by the Society's Technology Transfer office, Garching Innovation. SuppreMol's principal objective is to prove the therapeutic efficacy of a soluble Fc receptor in the treatment of Idiopathic Thrombocytopenic Purpura, Systemic Lupus Erythematosus, Rheumatoid Arthritis and other autoimmune diseases.
Topics
Organizations
Other news from the department business & finance
These products might interest you
Rotating ring disk electrode-3A Rotator by C3 Prozess- und Analysentechnik
Precise rotation and easy electrode change - Discover the innovative Rotator system!
VOLTAMMETRY CELLS by C3 Prozess- und Analysentechnik
Replace many sensing elements with our versatile voltammetry cell for precise measurement results
Interface 1010™ by C3 Prozess- und Analysentechnik
Optimize your electrochemical measurements for precise results and a wide range of applications
Reference 620 by C3 Prozess- und Analysentechnik
Potentiostat / Galvanostat / ZRA with maximum sensitivity and minimum noise for pioneering research
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.